Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company
of J&J
Description:
Pulmonary Arterial Hypertension (PAH) is a progressive vascular
disorder characterized by vascular remodeling of the pulmonary
arteries which carry blood from the heart to the lungs. For those
with PAH, the muscles within the arterial walls tighten, which can
cause thickening and/or scar tissue to develop, increasingly
narrowing their diameter. This leads to a progressive increase in
pulmonary vascular resistance that leads to right ventricular
failure and significant morbidity and mortality. Over time, the
heart muscle can become so weakened that its ability to pump enough
blood through the body is lost, leading to heart failure. The
estimated prevalence is between 15 and 50 cases per million
individuals and about half of people diagnosed with PAH will not
live past five years, while those with untreated PAH have an average
survival expectancy of approximately three years following diagnosis
– and even with aggressive management, PAH has a 15% annual
mortality rate.
Upon completion of this
activity, participants will be able to:
-
Discuss how guideline recommendations, pathophysiology, and
diagnostic criteria of PAH can achieve a patient’s therapeutic
goals
-
Explore current and emerging therapies in the treatment of PAH
-
Assess the major clinical trial data that supports the use of
combination therapy
-
Identify optimal management plans that review the side effect
profile and adverse events associated with PAH treatment
-
Evaluate innovative strategies that bridge the gaps in access to
new and emerging therapies for PAH, including the navigation of
managed care complexities and cost considerations
Faculty:
Richard Channick, MD
Saul Brandman Chair in Pulmonary Arterial Hypertension
Co-Director, Pulmonary Vascular Disease Program
UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
rchannick@mednet.ucla.edu
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance,
independence, objectivity, and scientific rigor in all of their
activities. All faculty participating in this activity are required
to disclose to NAMCP/AAMCN any financial relationships with
ineligible companies. NAMCP/AAMCN in turn discloses all relevant
financial conflicts to the learners. NAMCP/AAMCN disclosure policy
adheres to The Standards for Integrity and Independence in
Accredited Continuing Education. All relevant conflicts of interest
have been mitigated prior to the commencement of the activity. See
below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Channick has served as a consultant for Gossamer, Liquidia,
Johnson and Johnson, Merck, and Respira. He has received
grant/research support from Aria CV. He has served as a speaker for
Johnson and Johson and Merck. All relevant financial relationships
have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships
with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an
ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an
ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship
with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions
for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring
material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
NAMCP and/or this website do not provide medical advice, diagnosis,
or treatment. NAMCP does not endorse or imply endorsement of the
content on any linked website. This website is to be used as an
informational resource. With any health-related concern, consult
with your physician or healthcare professional.
This activity is supported by an educational grant from
Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company
of J&J
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |